Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 91 to 105 of 185 results for pembrolizumab

  1. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued Reference number: GID-TA10330

    Technology appraisal guidance
    Discontinued

  2. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued Reference number: GID-TA10418

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]

    Discontinued Reference number: GID-TA10295

    Technology appraisal guidance
    Discontinued

  4. Pembrolizumab for previously treated endometrial cancer [ID1205]

    Discontinued Reference number: GID-TA10243

    Technology appraisal guidance
    Discontinued

  5. Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]

    Discontinued Reference number: GID-TA10811

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]

    Discontinued Reference number: GID-TA10322

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development Reference number: GID-TA10696 Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma [ID3856]

    Discontinued Reference number: GID-TA10836

    Technology appraisal guidance
    Discontinued

  9. Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]

    Discontinued Reference number: GID-TA10697

    Technology appraisal guidance
    Discontinued

  10. Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

    Discontinued Reference number: GID-TA10668

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    Awaiting development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993]

    Awaiting development Reference number: GID-TA10896 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]

    Discontinued Reference number: GID-TA10413

    Technology appraisal guidance
    Discontinued

  15. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808]

    Awaiting development Reference number: GID-TA11200 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development